Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Kyu‐pyo Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7848-5923; OpenAlex author ID A5044558998. Sources: OpenAlex.

Their work

Papers
45 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
134
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: 4 papers · 2020: 6 papers · 2021: 5 papers · 2022: 5 papers · 2023: 4 papers · 2024: 5 papers · 2025: 4 papers · 2026: 2 papers

Papers 45

  1. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  2. Updates on Imaging Assessment of Pancreatic Cancer for Determining Anatomic and Biologic Resectability. Last author DOI 10.3348/kjr.2026.0341↗
  3. Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia. Co-author DOI 10.1016/j.esmogo.2025.100158↗
  4. Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine Learning. Co-author DOI 10.1200/cci-25-00124↗
  5. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16437-9↗
  6. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16618-6↗
  7. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Co-author DOI 10.1007/s00261-024-04299-4↗
  8. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Co-author DOI 10.1016/j.ejca.2024.114194↗
  9. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  10. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000001389↗
  11. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.977↗
  12. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study P… First author DOI 10.1093/oncolo/oyad022↗
  13. PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis. Last author DOI 10.21873/anticanres.16754↗
  14. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  15. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Co-author DOI 10.4143/crt.2023.452↗
  16. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Co-author DOI 10.1002/jhbp.1192↗
  17. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  18. Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review. Co-author DOI 10.21037/cco-21-166↗
  19. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism i… Co-author DOI 10.3390/cancers14030559↗
  20. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  21. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.1007/s00330-020-07134-8↗
  22. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Co-author DOI 10.1007/s00330-020-07188-8↗
  23. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Co-author DOI 10.1093/bjs/znab229↗
  24. Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventiona… Co-author DOI 10.1177/17588359211003053↗
  25. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model. Co-author DOI 10.3390/cells10102734↗
  26. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  27. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of … Co-author DOI 10.1148/radiol.2020200281↗
  28. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcin… Co-author DOI 10.1177/1758835920923424↗
  29. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  30. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderli… Co-author DOI 10.3390/jcm9051477↗
  31. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
  32. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammat… Co-author DOI 10.1007/s10637-018-0681-y↗
  33. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  34. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korea… Co-author DOI 10.1177/1758835919871126↗
  35. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  36. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
  37. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  38. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Co-author DOI 10.4143/crt.2017.494↗
  39. Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients. Co-author DOI 10.1186/s12935-017-0416-8↗
  40. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Co-author DOI 10.18632/oncotarget.17940↗
  41. Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin. Co-author DOI 10.21873/anticanres.11374↗
  42. SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. Co-author DOI 10.1007/s13277-015-4216-2↗
  43. Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer m… First author DOI 10.18632/oncotarget.12668↗
  44. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic … Co-author DOI 10.18632/oncotarget.4822↗
  45. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Co-author DOI 10.1016/j.humpath.2014.06.030↗

Closest collaborators

The 25 strongest of 134 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changhoon Yoo · 34 shared papers, 2017–2026 · strength 4.65
  2. Baek‐Yeol Ryoo · 27 shared papers, 2017–2026 · strength 3.28
  3. Song Cheol Kim · 27 shared papers, 2014–2026 · strength 3.26
  4. Dae Wook Hwang · 23 shared papers, 2017–2026 · strength 2.99
  5. Ki Byung Song · 18 shared papers, 2014–2026 · strength 2.02
  6. Seung Soo Lee · 10 shared papers, 2020–2026 · strength 1.92
  7. Woohyung Lee · 10 shared papers, 2020–2026 · strength 1.67
  8. Tae Jun Song · 14 shared papers, 2017–2026 · strength 1.65
  9. Jin‐hong Park · 14 shared papers, 2014–2026 · strength 1.54
  10. Seung‐Mo Hong · 12 shared papers, 2014–2025 · strength 1.52
  11. Do Hyun Park · 13 shared papers, 2017–2024 · strength 1.40
  12. Sang Soo Lee · 14 shared papers, 2014–2024 · strength 1.36
  13. Jae Ho Byun · 8 shared papers, 2020–2025 · strength 1.24
  14. Jin Hee Kim · 8 shared papers, 2020–2025 · strength 1.24
  15. Hyoung Jung Kim · 7 shared papers, 2020–2025 · strength 1.15
  16. Dong Wan Seo · 10 shared papers, 2017–2025 · strength 1.08
  17. Dongwook Oh · 7 shared papers, 2020–2026 · strength 1.07
  18. Dong‐Wan Seo · 7 shared papers, 2014–2025 · strength 0.92
  19. Jong Keon Jang · 5 shared papers, 2021–2025 · strength 0.91
  20. Yejong Park · 6 shared papers, 2020–2024 · strength 0.87
  21. Bong Jun Kwak · 5 shared papers, 2022–2024 · strength 0.78
  22. Inkeun Park · 4 shared papers, 2024–2026 · strength 0.76
  23. Hyehyun Jeong · 4 shared papers, 2020–2026 · strength 0.70
  24. Myung‐Hwan Kim · 8 shared papers, 2017–2022 · strength 0.64
  25. Se Jin Choi · 3 shared papers, 2022–2025 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.